Teglicar is primarily used in the field of metabolic research, particularly in the study of diabetes and obesity. It functions as an inhibitor of carnitine palmitoyltransferase 1 (CPT1), an enzyme crucial for fatty acid oxidation. By inhibiting CPT1, Teglicar helps researchers understand the metabolic pathways involved in lipid metabolism and energy homeostasis. This makes it a valuable tool in exploring potential therapeutic strategies for metabolic disorders, such as improving insulin sensitivity or reducing lipid accumulation in tissues. Additionally, Teglicar is utilized in preclinical studies to investigate its effects on liver function and its potential role in managing non-alcoholic fatty liver disease (NAFLD). Its application extends to studying the interplay between lipid metabolism and other physiological processes, offering insights into the development of novel treatments for metabolic diseases.